Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats.
Qingmiao ShaoLei MengSharen LeeGary TseMengqi GongZhiwei ZhangJichao ZhaoYungang ZhaoGuangping LiTong LiuPublished in: Cardiovascular diabetology (2019)
Empagliflozin can ameliorate atrial structural and electrical remodeling as well as improve mitochondrial function and mitochondrial biogenesis in T2DM, hence may be potentially used in the prevention of T2DM-related atrial fibrillation.
Keyphrases
- diabetic rats
- high fat diet
- atrial fibrillation
- oxidative stress
- catheter ablation
- left atrial
- insulin resistance
- adipose tissue
- oral anticoagulants
- left atrial appendage
- direct oral anticoagulants
- heart failure
- percutaneous coronary intervention
- glycemic control
- mitral valve
- metabolic syndrome
- skeletal muscle
- type diabetes
- acute coronary syndrome
- venous thromboembolism
- coronary artery disease